Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 7/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | DEGS1 | O15121 | 3/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22364264 | 0.86 | XDH (0.45) | XDHAHRNPC1ALDH1A1 | |
| SCHEMBL20929146 | 0.74 | FGFR4 (0.45) | XDHMEN1KMT2ADEGS1NPC1 | |
| SCHEMBL22364246 | 0.69 | XDH (0.68) | XDH | |
| SCHEMBL20915733 | 0.66 | XDH (0.69) | XDH | |
| SCHEMBL20915854 | 0.65 | XDH (0.68) | XDH | |
| SCHEMBL22364252 | 0.65 | XDH (0.67) | XDH | |
| SCHEMBL22241681 | 0.61 | PCSK9 (0.49) | — | |
| SCHEMBL23326033 | 0.61 | NISCH (0.40) | NPC1ALDH1A1L3MBTL1 | |
| SCHEMBL22381452 | 0.60 | XDH (0.65) | XDHMEN1KMT2AALDH1A1HTT | |
| SCHEMBL17941585 | 0.60 | XDH (0.65) | XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3481819-B1 | COMPOUNDS AND THEIR USE FOR REDUCING URIC ACID LEVELS | ACQUIST LLC (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-3481819-B1 | COMPOUNDS AND THEIR USE FOR REDUCING URIC ACID LEVELS | ACQUIST LLC (US) | 2022-06-01 | — | — | EP | disclosed |
| US-20220024900-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2022-01-27 | — | — | US | disclosed |
| US-20220024900-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2022-01-27 | — | — | US | disclosed |
| CN-109476642-B | Compounds and their use for reducing uric acid levels | 阿奎斯特有限责任公司 | 2022-01-25 | — | — | CN | disclosed |
| US-11168075-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2021-11-09 | — | — | US | disclosed |
| US-11168075-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210236495-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2021-08-05 | — | — | US | disclosed |
| US-20210236495-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2021-08-05 | — | — | US | disclosed |
| US-11020397-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2021-06-01 | — | — | US | disclosed |
| US-10759784-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2020-09-01 | — | — | US | disclosed |
| US-10759784-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2020-09-01 | — | — | US | disclosed |
| US-20200268757-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2020-08-27 | — | — | US | disclosed |
| US-20200268757-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2020-08-27 | — | — | US | disclosed |
| US-20200197393-A9 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC | 2020-06-25 | — | — | US | disclosed |
| US-20200197393-A9 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC | 2020-06-25 | — | — | US | disclosed |
| US-10688095-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2020-06-23 | — | — | US | disclosed |
| US-10688095-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190117654-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2019-04-25 | — | — | US | disclosed |
| US-20190117654-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024900-A1 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, PON1 | XDH 1/4885MEN1 2769/4885KMT2A 3084/4885 |
| US-11168075-B2 | Compounds and their use for reducing uric acid levels | XDH, OAT, PON1 | XDH 1/4885MEN1 2769/4885KMT2A 3084/4885 |
| US-10688095-B2 | Compounds and their use for reducing uric acid levels | XDH, OAT, UGT2B7 | XDH 1/4885MEN1 2537/4885KMT2A 2533/4885 |
| US-20210236495-A1 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, URB2 | XDH 1/4885MEN1 3166/4885KMT2A 3100/4885 |
| US-20200268757-A1 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, URB2 | XDH 1/4885MEN1 3166/4885KMT2A 3100/4885 |
| US-10759784-B2 | Compounds and their use for reducing uric acid levels | XDH, OAT, PON1 | XDH 1/4885MEN1 2769/4885KMT2A 3084/4885 |
| US-11020397-B2 | Compounds and their use for reducing uric acid levels | XDH, OAT, UGT2B7 | XDH 1/4885MEN1 2537/4885KMT2A 2533/4885 |
| US-20200197393-A9 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, URB2 | XDH 1/4885MEN1 3166/4885KMT2A 3100/4885 |
| US-20190117654-A1 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, URB2 | XDH 1/4885MEN1 3166/4885KMT2A 3100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.